Key result
SGLT inhibitors cut serious AF events by ~25% versus placebo or no therapy.
Why the study?
SGLT inhibitors reduce cardiovascular outcomes including mortality in several populations, but their effect on atrial fibrillation or flutter remains unclear.
Do SGLT inhibitors reduce atrial fibrillation events and the composite of heart failure hospitalization or cardiovascular death in patients with and without a history of AF?
Meta-Analysis (n=75,279)
Do SGLT inhibitors reduce atrial fibrillation events and the composite of heart failure hospitalization or cardiovascular death in patients with and without a history of AF?
Effect estimate: RR 0.75 (95% CI 0.66-0.86)
Absolute Event Rate: 1.1% vs 1.5%
SGLT inhibitors reduce the risk of serious atrial fibrillation events and lower the risk of heart failure hospitalization or cardiovascular death similarly in patients with and without a history of AF.
No takes yet. Share an insight, caveat, or question.
Supports SGLT inhibitors to reduce serious AF events; confirms similar HFH/CV death benefit regardless of prior AF history.
Pandey et al. (2021) conducted a meta-analysis in Atrial fibrillation (n=75,279). Sodium-glucose co-transporter (SGLT) inhibitors vs. Placebo or no therapy was evaluated on Serious atrial fibrillation events (RR 0.75, 95% CI 0.66-0.86). SGLT inhibitors significantly reduced the risk of serious atrial fibrillation events compared to placebo or no therapy (1.1% vs 1.5%; RR 0.75; 95% CI 0.66-0.86).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: